Analytical technologies for influenza virus-like particle candidate vaccines: Challenges and emerging approaches

  1. Get@NRC: Analytical technologies for influenza virus-like particle candidate vaccines: Challenges and emerging approaches (Opens in a new window)
DOIResolve DOI:
AuthorSearch for: ; Search for: ; Search for: ; Search for: ; Search for:
Journal titleVirology Journal
Article number141
Subjectinfluenza vaccine; influenza virus like particle vaccine; unclassified drug; virus protein; cell strain HEK293; DNA vector; electron microscopy; enzyme activity; enzyme linked immunosorbent assay; HeLa cell; immunodiffusion; Influenza virus; insect cell; protein analysis; reversed phase high performance liquid chromatography; review; Vero cell; virion; virus hemagglutination; virus strain; Western blotting; Orthomyxoviridae
AbstractInfluenza virus-like particle vaccines are one of the most promising ways to respond to the threat of future influenza pandemics. VLPs are composed of viral antigens but lack nucleic acids making them non-infectious which limit the risk of recombination with wild-type strains. By taking advantage of the advancements in cell culture technologies, the process from strain identification to manufacturing has the potential to be completed rapidly and easily at large scales. After closely reviewing the current research done on influenza VLPs, it is evident that the development of quantification methods has been consistently overlooked. VLP quantification at all stages of the production process has been left to rely on current influenza quantification methods (i.e. Hemagglutination assay (HA), Single Radial Immunodiffusion assay (SRID), NA enzymatic activity assays, Western blot, Electron Microscopy). These are analytical methods developed decades ago for influenza virions and final bulk influenza vaccines. Although these methods are time-consuming and cumbersome they have been sufficient for the characterization of final purified material. Nevertheless, these analytical methods are impractical for in-line process monitoring because VLP concentration in crude samples generally falls out of the range of detection for these methods. This consequently impedes the development of robust influenza-VLP production and purification processes. Thus, development of functional process analytical techniques, applicable at every stage during production, that are compatible with different production platforms is in great need to assess, optimize and exploit the full potential of novel manufacturing platforms. © 2013 Thompson et al.; licensee BioMed Central Ltd.
Publication date
AffiliationNational Research Council Canada (NRC-CNRC); Human Health Therapeutics (HHT-TSH)
Peer reviewedYes
NPARC number21269975
Export citationExport as RIS
Report a correctionReport a correction
Record identifierc21848bf-d808-44a0-a341-ec9e862aad69
Record created2013-12-13
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)